Compare ONEW & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEW | ZURA |
|---|---|---|
| Founded | 2014 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 595.9M |
| IPO Year | 2019 | N/A |
| Metric | ONEW | ZURA |
|---|---|---|
| Price | $8.60 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $16.75 | $11.78 |
| AVG Volume (30 Days) | 139.9K | ★ 520.3K |
| Earning Date | 04-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | $3.04 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $8.12 | $0.99 |
| 52 Week High | $18.15 | $7.25 |
| Indicator | ONEW | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 36.66 |
| Support Level | N/A | $3.33 |
| Resistance Level | $12.51 | $5.75 |
| Average True Range (ATR) | 0.68 | 0.53 |
| MACD | -0.13 | -0.17 |
| Stochastic Oscillator | 15.16 | 3.73 |
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.